drugset / Trial / NCT05019105
Phase 1 ALKS 1140 in Healthy Adults
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the safety and tolerability of ALKS 1140 in healthy adult subjects
Timeline
- Start
- 2021-10-13
- Primary completion
- 2022-08-23
- Completion
- 2022-08-23
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ALKS 1140 | Unknown | — | Oral |